首页 | 本学科首页   官方微博 | 高级检索  
     

18F-FDG PET/CT早期监测小剂量顺铂在体化疗敏感性的实验研究
引用本文:宋少莉,刘建军,王兆海,万良荣,孙晓光,黄钢.18F-FDG PET/CT早期监测小剂量顺铂在体化疗敏感性的实验研究[J].核技术,2009,32(8).
作者姓名:宋少莉  刘建军  王兆海  万良荣  孙晓光  黄钢
作者单位:1. 上海交通大学医学院附属仁济医院核医学科,上海,200127;上海交通大学临床核医学研究所,上海,200127
2. 解放军第302医院肝阳外科,北京,100039
基金项目:上海市重点学科建设项目,上海市科委重点项目,上海交通大学博士创新项目,上海交通大学医学院附属仁济医院一基础医学院合作项,上海交通大学医工合作专项一小动物PET/CT成像研究项目 
摘    要:42只双侧前胸壁荷瘤的VX2兔模型(共计84个肿瘤)随机分为治疗组(n=32)和对照组(n=10).治疗组静脉给予4mg/kg顺铂前(Pre-therapy)和给药后95-100min(Day 0)、Day 1、Day7、Day 14行PET/CT显像;对照组不给化疗药物,其余与实验组相同.取葡萄糖摄取最大值(SUVmax)进行分析,CT测量肿瘤大小.按肿瘤体积分组,Day 7时治疗组肿瘤体积增长>1倍则为不敏感,反之为敏感.结果显示:(1)Day 0敏感组SUVmax减低率为(-48.96±12.27)%,而不敏感组和对照组为(21.26±18.26)%和(7.16±13.47)%,三组SUVmax变化有显著差异(P<0.05).(2)Pre-therapy、Day 0、Day 1、Day 14两组肿瘤体积无显著性差异(P>0.05),但Day 7敏感组肿瘤体积小于不敏感组及对照组,差异有显著性(P<0.05).(3)Day 7、Day 14敏感组肿瘤坏死率大于不敏感组及对照组,差异有显著性(P<0.05).(4)HE染色观察不同时间点切除的肿瘤标本发现:Day 7、Day 14时敏感组肿瘤细胞数少而炎性和坏死细胞数增加.表明根据化疗药物给予后FDG减低程度,18F-FDG PET/CT能在体、早期、灵敏检出肿瘤对化疗药物的敏感性.

关 键 词:VX2肿瘤模型  18F-脱氧葡萄糖  正电子发射型计算机断层扫描/计算机断层扫描仪  化疗敏感性  在体  监测

Early in vivo monitoring chemosensitivity to low dose cisplatin of VX2 xenografts in rabbits by 18F-FDG PET/CT
SONG Shaoli,LIU Jianjun,WANG Zhaohai,WAN Liangrong,SUN Xiaoguang,HUANG Gang.Early in vivo monitoring chemosensitivity to low dose cisplatin of VX2 xenografts in rabbits by 18F-FDG PET/CT[J].Nuclear Techniques,2009,32(8).
Authors:SONG Shaoli  LIU Jianjun  WANG Zhaohai  WAN Liangrong  SUN Xiaoguang  HUANG Gang
Abstract:This study is to explore the feasibility of using 18F-FDG PET/CT as an in vivo individual chemosensitivitytesting method.Forty-two VX2 rabbits bearing a total of 84 tumors were randomized into treatment group (n=32) and control group (n=10).18F-FDG PET/CT was performed the day before intravenous administration of cisplatin (4 mg/kg) and at 95-100 min (Day 0),Day 1,Day 7,and Day 14 afterward.The control group,without cisplatin ad-ministration,received the 18F-FDG PET/CT imaging at the same time points.Maximum standardized uptake value (SUV) was analyzed.The animals on Day 7 with a tumor volume of at least twice as larger than Day 0,were regarded as the sensitive group (SG),while the others the insensitive group (ISG).The results showed that a significant differ-ence (P<0.05) in SUV on Day 0 between SG and ISG,with SUV decrease rate of (-48.96±12.27)%,(21.26±18.26)%and (7.16±13.47)% for SG,ISG and the control,respectively.No significant difference in tumor volume was found among the three groups pre-therapy and on Day 0 and Day 1.On Day 7,however,the tumor volume with SG was smaller than with ISG,in a significant difference of P<0.05,while no significant difference was seen between ISG and the control on Day 7.On Day 14,no significant difference was observed among the tumor volume of the three groups (P>0.05).On Day 7 and Day 14,significant differences were seen in tumor necrosis rate in SG and ISG (P<0.05),but no significant differences were seen between ISG and the control.Paraffin section stained with haema-toxylin and eosin of sections obtained at different time showed that the number of viable tumor cells in sensitive group diminished than ISG and the control,and inflammation and necrotic cells were increased on Day 7 and Day 14.The study showed that 18F-FDG PET/CT can be used as an in vivo chemosensitivity testing method.According to the decrease rate when cisplatin adminstration,PET can early in vivo sensitively differentiate the sensitive and insensitive tumors.
Keywords:VX2 tumor model  18F-fluorodeoxyglucose(18F-FDG)  Positron emission tomography/computed tomo-graphy(PET/CT)  Chemosensitivity  In vivo  Monitor
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号